28442401|t|TRIB3 downregulation enhances doxorubicin - induced cytotoxicity in gastric cancer cells
28442401|a|TRIB3, which is a pseudokinase known to regulate multiple pro-survival pathways, appears to be a potential therapeutic target for the treatment of human tumors. However, its precise role in cancer is controversial, as TRIB3 protein levels have been associated with both good and poor prognosis in cancer patients. Here, we investigated the significance of TRIB3 expression in the survival of gastric cancer cells exposed to anticancer drugs. We found that the tested anticancer drug, doxorubicin, induced cytotoxicity by decreasing TRIB3 transcription, which was followed by apoptotic cell death. Moreover, TRIB3 siRNA knockdown appeared to enhance doxorubicin - induced apoptosis in gastric cancer cells, concurrently with altering the expression of downstream apoptotic factors. Conversely, overexpression of TRIB3 significantly protected cells against doxorubicin - induced apoptosis. Our results indicate that downregulation of TRIB3 appears to promote cell death and enhance doxorubicin - induced apoptosis, supporting the anti-apoptotic role of TRIB3. The inductions of three classes of MAPKs failed to affect doxorubicin -mediated TRIB3 downregulation, while TRIB3 overexpression did not affect doxorubicin - induced MAPK activation. In sum, our findings indicate that TRIB3 plays an anti-apoptotic role in doxorubicin -treated gastric cancer cell lines, perhaps indicating that the status of TRIB3 expression in response to anticancer drugs, such as doxorubicin, irinotecan or oxaliplatin, may reflect the efficiency for cancer therapy.
28442401	0	5	TRIB3	T116,T123	C1259051
28442401	6	20	downregulation	T044	C0013081
28442401	21	29	enhances	T052	C2349975
28442401	30	41	doxorubicin	T109,T195	C0013089
28442401	44	51	induced	T169	C0458082
28442401	52	64	cytotoxicity	T049	C0596402
28442401	68	82	gastric cancer	T191	C0024623
28442401	83	88	cells	T025	C0334227
28442401	89	94	TRIB3	T116,T123	C1259051
28442401	107	119	pseudokinase	T116,T123	C0033684
28442401	129	168	regulate multiple pro-survival pathways	T038	C1327622
28442401	196	207	therapeutic	T061	C0087111
28442401	208	214	target	T169	C1521840
28442401	223	232	treatment	T061	C0920425
28442401	236	241	human	T016	C0086418
28442401	242	248	tumors	T191	C0027651
28442401	279	285	cancer	T191	C0006826
28442401	307	312	TRIB3	T116,T123	C1259051
28442401	313	327	protein levels	T034	C0428479
28442401	359	363	good	T033	C0278250
28442401	368	382	poor prognosis	T033	C0278252
28442401	386	401	cancer patients	T101	C1516213
28442401	445	450	TRIB3	T116,T123	C1259051
28442401	451	461	expression	T045	C1171362
28442401	469	477	survival	T043	C0007620
28442401	481	495	gastric cancer	T191	C0024623
28442401	496	501	cells	T025	C0334227
28442401	513	529	anticancer drugs	T109,T121	C0003392
28442401	549	555	tested	T169	C0039593
28442401	556	571	anticancer drug	T109,T121	C0003392
28442401	573	584	doxorubicin	T109,T195	C0013089
28442401	586	593	induced	T169	C0458082
28442401	594	606	cytotoxicity	T049	C0596402
28442401	621	626	TRIB3	T028	C1540055
28442401	627	640	transcription	T045	C0040649
28442401	664	684	apoptotic cell death	T043	C0162638
28442401	696	707	TRIB3 siRNA	T114,T123	C1099354
28442401	708	717	knockdown	T063	C2350567
28442401	730	737	enhance	T052	C2349975
28442401	738	749	doxorubicin	T109,T195	C0013089
28442401	752	759	induced	T169	C0458082
28442401	760	769	apoptosis	T043	C0162638
28442401	773	787	gastric cancer	T191	C0024623
28442401	788	793	cells	T025	C0334227
28442401	826	836	expression	T045	C1171362
28442401	840	850	downstream	T082	C0522506
28442401	851	868	apoptotic factors	T116,T123	C0763396
28442401	882	896	overexpression	T045	C1514559
28442401	900	905	TRIB3	T116,T123	C1259051
28442401	920	935	protected cells	T025	C0007634
28442401	944	955	doxorubicin	T109,T195	C0013089
28442401	958	965	induced	T169	C0458082
28442401	966	975	apoptosis	T043	C0162638
28442401	1003	1017	downregulation	T044	C0013081
28442401	1021	1026	TRIB3	T116,T123	C1259051
28442401	1038	1045	promote	T052	C0033414
28442401	1046	1056	cell death	T043	C0007587
28442401	1061	1068	enhance	T052	C2349975
28442401	1069	1080	doxorubicin	T109,T195	C0013089
28442401	1083	1090	induced	T169	C0458082
28442401	1091	1100	apoptosis	T043	C0162638
28442401	1117	1131	anti-apoptotic	T120	C2986514
28442401	1140	1145	TRIB3	T116,T123	C1259051
28442401	1151	1161	inductions	T045	C0017391
28442401	1182	1187	MAPKs	T116,T126	C0752312
28442401	1205	1216	doxorubicin	T109,T195	C0013089
28442401	1227	1232	TRIB3	T116,T123	C1259051
28442401	1233	1247	downregulation	T044	C0013081
28442401	1255	1260	TRIB3	T116,T123	C1259051
28442401	1261	1275	overexpression	T045	C1514559
28442401	1291	1302	doxorubicin	T109,T195	C0013089
28442401	1305	1312	induced	T169	C0458082
28442401	1313	1328	MAPK activation	T044	C1155551
28442401	1342	1350	findings	T033	C2825141
28442401	1365	1370	TRIB3	T116,T123	C1259051
28442401	1380	1394	anti-apoptotic	T120	C2986514
28442401	1403	1414	doxorubicin	T109,T195	C0013089
28442401	1424	1438	gastric cancer	T191	C0024623
28442401	1439	1449	cell lines	T025	C0334227
28442401	1489	1494	TRIB3	T116,T123	C1259051
28442401	1495	1505	expression	T045	C1171362
28442401	1521	1537	anticancer drugs	T109,T121	C0003392
28442401	1547	1558	doxorubicin	T109,T195	C0013089
28442401	1560	1570	irinotecan	T109,T121	C0123931
28442401	1574	1585	oxaliplatin	T109,T121	C0069717
28442401	1618	1632	cancer therapy	T061	C0920425